|
|
|
 
 
 
 
|
|
|
|
|
||
|
| ||||
| ||||
| ||||
| ||||
| ||||
|
|
|
Johnson and Johnson Stock ready to move up
Johnson and Johnson (Ticker: JNJ) is showing bullish pattern and steady accumulation by smart money. It can appreciate twenty five to forty percent over the next 14 months. JNJ’s aggressive internationalization, creation of Splenda – the miracle of Sugar alternative are all working for the company. We are expecting a target price of $86 by next summer.
Ortho Biotech Products said a study demonstrated that Procrit increased hemoglobin levels more than Aranesp in patients with cancer and anemia caused by chemotherapy.
In a press release, the company said the results showed that 47% of patients treated with Procrit achieved the primary endpoint of the study, an increase in hemoglobin of one gram or more per deciliter of blood within the first four weeks, compared with 33% of patients who were treated with Aranesp. The difference was statistically significant, Ortho said.
A study presented today at the 41st Annual Meeting of the American Society for Clinical Oncology demonstrated that PROCRIT® (Epoetin alfa) increased hemoglobin -- or red blood cell -- levels more than Aranesp® (darbepoetin alfa) in patients with cancer and anemia caused by chemotherapy. The study found that 47 percent of patients treated with PROCRIT achieved the primary endpoint of the study, an increase in hemoglobin of one gram or more per deciliter of blood (g/dL), within the first four weeks of the study, compared to 33 percent of patients who were treated with Aranesp, a statistically significant difference.
Johnson & Johnson is engaged in the manufacture and sale of products related to human health and well-being. Through over 200 operating companies, it conducts business worldwide. The Company's business is divided into three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment manufactures and markets a range of products used in the baby and child care, skin care, oral and wound care and women's healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment's principal worldwide franchises are in the antifungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic and urology fields. The Medical Devices and Diagnostics segment includes a range of products used by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics.
Disclaimer: Trade at your own risk. We are not responsible for any loss. This is just an opinion. Trading in futures or stocks in the market is risky.
US ELECTION ARTICLES
|
|
| Click here to get ad specs and place your ad or Click here to contact the advertisement department |
Send Letters to the Editor
|
Add RSS headlines